Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. The company is self-described as working to create a people-centered environment.

Arthrosi Therapeutics, Inc.

Arthrosi Therapeutics, Inc. | 596 followers on LinkedIn. Arthrosi is a clinical-stage biotech company focused on developing game-changing therapy for gout and tophaceous gout. | Arthrosi Therapeutics is a leading clinical-stage biotech company dedicated to advancing therapies for gout disease. Our proprietary oral drug candidate, AR882 which is currently in clinical Phase 3, has demonstrated unprecedented sustained urate lowering in gout patients and reduction of tophi, showing exceptional potential to treat millions of patients suffering from gout and tophaceous gout. At Arthrosi Therapeutics, we are committed to transforming the treatment landscape and improving the lives of patients worldwide.

Sr. Director, Clinical Operations at Arthrosi Therapeutics

Liz Polvent

Bioanalytical Scientist

Andrea Clouser Roche

Founder, COO at Arthrosi Therapeutics

Shunqi Yan (颜顺启), Ph.D.

Co-Founder & CEO, Arthrosi Therapeutics, Inc.

Litain Yeh

We’ve just updated our page. Visit us to see the latest updates.

ARTH

COM:ARTHROSI

Arthrosi Therapeutics, Inc.